IP Library Granted Patent US 10,464,968
Granted Patent B2
US 10,464,968 · App. 16/025,344 · Granted Nov 5, 2019

Method for producing a composition for treating a tooth lesion

Inventors: Michael Hug (Zofingen, CH); Dominikus Amadeus Lysek (Windisch, CH)
Assignee: Credentis AG
C07K7/06A61C5/68A61K6/0017A61K38/17C07K1/00A61K38/00C03C2205/06Y10S522/908
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,464,968
App. No.
16/025,344
Granted
Nov 5, 2019
Kind
B2
Abstract

The invention relates to a method for preparing a composition for treating a tooth lesion, said composition comprising peptides that are capable of undergoing self-assembly at a certain pH. The compositions of the invention are highly suitable for being used in the medical field, in particular for remineralising a tooth lesion such as a subsurface caries lesion.

Claims (11)

1. A composition in lyophilized undissolved form comprising

a peptide that undergoes self-assembly at a pH value below 7.5, wherein the peptide is predominantly in a monomeric form;

a non-reducing sugar; and

a non-volatile buffer;

wherein upon reconstitution of the composition in water, a solution with an ionic strength of less than 0.15 and a pH that is 0.1 to 0.5 pH units above the pH at which the peptide starts to undergo self-assembly is obtained in which the peptide is predominantly present in a monomeric form.

2. The composition of claim 1 , wherein said peptide comprises the sequence of SEQ ID NO:3.

3. The composition of claim 1 , wherein said peptide comprises the sequence of SEQ ID NO: 4 or SEQ ID NO: 5.

4. The composition of claim 1 , wherein said peptide comprises the sequence depicted in SEQ ID NO:1 or SEQ ID NO:2 or a sequence having at least 80% sequence identity thereto.

5. The composition of claim 1 , wherein at least 70% of the peptide are present in monomeric form.

6. The composition of claim 1 , wherein at least 80% of the peptide are present in monomeric form.

7. The composition of claim 1 , wherein at least 90% of the peptide are present in monomeric form.

Assignments (2)
SECURITY INTEREST Recorded Feb 7, 2025
From: CREDENTIS AG; SWISS SHINE BEAUTY AG; VVARDIS AG
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP
Reel/Frame 070139/0560 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2018
From: HUG, MICHAEL; LYSEK, DOMINIKUS AMADEUS
To: CREDENTIS AG
Reel/Frame 046705/0172 →
Priority Claims (1)
EP 12180578 · Aug 15, 2012 · regional
Continuity (2)
Continuation 14421666
Related Publication 20180340010A1 · Nov 29, 2018